Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate HCW Biologics Inc. before investing.

In this article, we go over a few key elements for understanding HCW Biologics Inc.’s stock price such as:

• HCW Biologics Inc.’s current stock price and volume
• Why HCW Biologics Inc.’s stock price changed recently
• Upgrades and downgrades for HCWB from analysts
• HCWB’s stock price momentum as measured by its relative strength

About HCW Biologics Inc. (HCWB)

Before we jump into HCW Biologics Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company’s lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer. The company has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Want to learn more about HCW Biologics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about HCW Biologics Inc..

HCW Biologics Inc.’s Stock Price as of Market Close

As of June 11, 2025, 12:58 PM, CST, HCW Biologics Inc.’s stock price was $5.350.

HCW Biologics Inc. is down 2.55% from its previous closing price of $5.490.

During the last market session, HCW Biologics Inc.’s stock traded between $5.200 and $5.480. Currently, there are approximately 44.68 million shares outstanding for HCW Biologics Inc..

HCW Biologics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

HCW Biologics Inc. Stock Price History

HCW Biologics Inc.’s (HCWB) price is currently down 30.79% so far this month.

During the month of June, HCW Biologics Inc.’s stock price has reached a high of $7.830 and a low of $5.200.

Over the last year, HCW Biologics Inc. has hit prices as high as $100.800 and as low as $5.000. Year to date, HCW Biologics Inc.’s stock is down 70.02%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused HCW Biologics Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 10, 2025, there were analysts who downgraded HCW Biologics Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate HCW Biologics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on HCW Biologics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about HCW Biologics Inc. (HCWB) by visiting AAII Stock Evaluator.

Relative Price Strength of HCW Biologics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 10, 2025, HCW Biologics Inc. has a weighted four-quarter relative price strength of -43.20%, which translates to a Momentum Score of 2 and is considered to be Very Weak.

Want to learn more about how HCW Biologics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

HCW Biologics Inc. Stock Price: Bottom Line

As of June 11, 2025, HCW Biologics Inc.’s stock price is $5.350, which is down 2.55% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like HCW Biologics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.